Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …

Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Importance Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging.
Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)–positive patients …

A recent case report described an individual who was a homozygous carrier of the APOE3
Christchurch (APOE3ch) mutation and resistant to autosomal dominant Alzheimer's Disease …

While blood-based tests are readily available for various conditions, including
cardiovascular diseases, type 2 diabetes, and common cancers, Alzheimer's disease (AD) …

Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require
evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal …

Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …

Objective A clock relating amyloid positron emission tomography (PET) to time was used to
estimate the timing of biomarker changes in sporadic Alzheimer disease (AD). Methods …

Current status of amyloid-targeting immunotherapies for Alzheimer’s disease | Science
Translational Medicine news careers commentary Journals Science Science brought to you …